Insulin Aspart Sanofi

Insulin Aspart, the active ingredient in Insulin Aspart Sanofi, is a rapid‑acting insulin analog presented as a solution for injection for subcutaneous or intravenous use. It treats hyperglycemia in people with type 1 and type 2 diabetes mellitus.

GNH USA supplies Insulin Aspart Sanofi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Insulin Aspart is a rapid‑acting insulin analog used to control blood glucose in diabetes mellitus.

- Type 1 diabetes mellitus: improves post‑prandial glucose control and reduces hyperglycaemic excursions. - Type 2 diabetes mellitus: assists in achieving glycaemic targets when combined with oral agents or basal insulin.

Insulin Aspart may cause a range of adverse reactions.

Common Side Effects: - Hypoglycaemia: low blood glucose levels, especially if meals are missed. - Injection site reactions: redness, swelling, or itching at the injection site. - Lipodystrophy: localized changes in subcutaneous fat with repeated injections. - Weight gain: modest increase associated with improved glycaemic control.

Serious or Rare Side Effects: - Severe hypoglycaemia leading to loss of consciousness or seizures. - Anaphylactic reaction: hives, difficulty breathing, or swelling of the face. - Hypersensitivity with angio‑edema or severe skin rash. - Development of insulin antibodies that may alter drug efficacy. - Edema: fluid retention, particularly in the lower extremities.

When using Insulin Aspart, several safety considerations are recommended.

- Dose adjustment: monitor blood glucose frequently and modify dose when meals, activity, or health status change. - Renal impairment: reduced clearance may require lower doses to avoid hypoglycaemia. - Hepatic impairment: use with caution as liver disease can affect glucose metabolism. - Pregnancy: limited data; prescribe only if potential benefit justifies potential risk to the fetus. - Hypoglycaemia risk: educate patients on recognising and treating low blood glucose promptly. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Insulin Aspart can interact with other medicines, altering its efficacy or safety.

Major Interactions (Avoid): - Beta‑blockers: may mask symptoms of hypoglycaemia, delaying treatment. - Monoamine oxidase inhibitors (MAOIs): can potentiate insulin’s glucose‑lowering effect. - Concurrent use of other insulins or secretagogues: increases risk of severe hypoglycaemia.

Moderate Interactions (Monitor Closely): - ACE inhibitors: may enhance insulin sensitivity, requiring dose review. - Thiazide diuretics: can raise blood glucose levels, potentially reducing insulin effectiveness.